IL-5 is the most important cytokine for the production, regulation and survival of eosinophils; this cytokine is blocked by mepolizumab, a monoclonal antibody directed against IL-5, which is the only approved biological therapy for I-HES so far (6). This evidence concerns the gene IL5 and hypereosinophilic syndrome.